Atossa Therapeutics Showcases (Z)-Endoxifen Data with Breast Cancer Expert
Event summary
- Atossa Therapeutics to host virtual KOL event on May 19, 2026 featuring Dr. Laura Esserman
- Discussion to focus on (Z)-endoxifen's potential as next-gen endocrine therapy for ER-positive breast cancer
- Key topics include I-SPY2 trial data, biomarker results, and combination therapy strategies
- Event moderated by Michael King of Rodman & Renshaw
- (Z)-endoxifen is currently unapproved but shows distinct pharmacology from tamoxifen
The big picture
Atossa Therapeutics is positioning (Z)-endoxifen as a potential backbone therapy for ER-positive breast cancer, competing in a space dominated by established endocrine treatments. The company's focus on biomarker-driven development and combination strategies reflects broader industry trends toward precision oncology. Success will depend on demonstrating superior efficacy and safety profiles compared to current standards of care.
What we're watching
- Clinical Validation
- How emerging I-SPY2 data will position (Z)-endoxifen against existing endocrine therapies
- Combination Strategies
- Whether CDK4/6 inhibitor combinations can expand (Z)-endoxifen's therapeutic potential
- Regulatory Pathway
- The pace at which Atossa can advance (Z)-endoxifen through clinical development
Related topics